menu
    • menu

    Company profile for Immatics

    NEW Drugs in Dev: 12
    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    Aarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.

    Virtual Booth

    Contact Supplier

    Axplora is your partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. Our transformative product candidates are - best in class - Adoptive Cell Therapies and TCR Bispecific molecules TCER™. These products are directed against tumor targets that have been identified and validated by Immatics' proprietary and world-leading XPRESIDENT...
    Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. Our transformative product candidates are - best in class - Adoptive Cell Therapies and TCR Bispecific molecules TCER™. These products are directed against tumor targets that have been identified and validated by Immatics' proprietary and world-leading XPRESIDENT® technology. Our mission is to deliver the power of T-cell redirecting immunotherapies to cancer patients.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ImmaticsGermany Flag
    Country
    Country
    Germany
    Address
    Address
    Paul-Ehrlich-Str. 15 72076 Tuebingen Germany
    Telephone
    Telephone
    +49 (7071) 5397-0
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://immatics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/immatics-biotechnologies/?originalSubdomain=de
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/immatics

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    BioProcess International US West

    Not Confirmed

    envelop Contact Supplier

    BioProcess International US West

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Immatics Reveals 2025 Financials And Business Progress
    Immatics Reveals 2025 Financials And Business Progress

    05 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/05/3250021/0/en/Immatics-Announces-Full-Year-2025-Financial-Results-and-Business-Update.html

    GLOBENEWSWIRE
    05 Mar 2026
    Share Share
    Immatics Reveals Positive IMA203CD8 PRAME Cell Therapy Data
    Immatics Reveals Positive IMA203CD8 PRAME Cell Therapy Data

    11 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/11/3203752/0/en/Immatics-Presents-IMA203CD8-PRAME-Cell-Therapy-Data-from-Ongoing-Dose-Escalation-and-Shows-Promising-Initial-Anti-tumor-Activity-in-PRAME-Positive-Tumors-at-ESMO-IO-2025-Congress.html

    GLOBENEWSWIRE
    11 Dec 2025
    Share Share
    Immatics Announces $125 Million Underwritten Offering
    Immatics Announces $125 Million Underwritten Offering

    05 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/05/3200531/0/en/Immatics-Announces-125-Million-Underwritten-Offering.html

    GLOBENEWSWIRE
    05 Dec 2025
    Share Share
    Immatics Reveals Q3 2025 Financials And Business Progress
    Immatics Reveals Q3 2025 Financials And Business Progress

    17 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/17/3188995/0/en/Immatics-Announces-Third-Quarter-2025-Financial-Results-and-Business-Update.html

    GLOBENEWSWIRE
    17 Nov 2025
    Share Share
    Immatics Hits TCER Milestone with IMA402 & IMA401
    Immatics Hits TCER Milestone with IMA402 & IMA401

    12 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/12/3186043/0/en/Immatics-Achieves-Clinical-Proof-of-Concept-of-its-Next-Generation-TCR-Bispecific-TCER-Pipeline-with-Data-on-IMA402-PRAME-and-IMA401-MAGEA4-8-and-Announces-Next-Development-Steps.html

    GLOBENEWSWIRE
    12 Nov 2025
    Share Share
    Immatics Appoints Amie Krause As Chief People Officer
    Immatics Appoints Amie Krause As Chief People Officer

    27 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/27/3174433/0/en/Immatics-Appoints-Amie-Krause-as-Chief-People-Officer.html

    GLOBENEWSWIRE
    27 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search